Spastic Paraplegia Type 50 research hub

Administration of MELPIDA to Determine the Safety and Efficacy for Patients With Spastic Paraplegia Type 50

This study is looking at a new treatment called MELPIDA for a rare genetic condition causing muscle stiffness and weakness, called Spastic Paraplegia Type 50 (SPG50). It's the first time this treatment is being tried in humans, focusing on its safety and whether it helps people with SPG50.